复方异丙托溴铵联合阿莫西林克拉维酸钾治疗大叶性肺炎患儿的效果  

Effect of compound ipratropium bromide combined with amoxicillin and clavulanate potassium in the treatment of children with lobar pneumonia

作　　者：柴娜娜 Chai Na-na(Department of Pediatric Medicine,Boai People's Hospital,Jiaozuo 454450,Henan,China)

机构地区：[1]博爱县人民医院小儿内科,河南焦作454450

出　　处：《四川生理科学杂志》2024年第12期2683-2685,共3页

摘　　要：目的:分析复方异丙托溴铵联合阿莫西林克拉维酸钾治疗大叶性肺炎患儿的疗效。方法:回顾性收集2021年6月至2023年7月期间本院收治的108例大叶性肺炎患儿的临床资料,按患者的不同治疗方案分为对照组和观察组,各54例。对照组采用阿莫西林克拉维酸钾治疗,300 mg·(kg·次)-1,静脉滴注,1次·d^(-1);观察组在对照组基础上加用复方异丙托溴铵气雾剂,2喷·次^(-1),2次·d^(-1)。治疗14 d后采用呼吸功能检测仪测定呼吸做功(Work of Breathing,WOB)、气道阻力(Airway Resistance,Raw)、气道峰压(Peak airway pressure,PIP);采用酶联免疫法测定白介素-17(Interleukin 17,IL-17)、白介素-33(Interleukin 33,IL-33)、高迁移率族蛋白B1(High mobility group box-1 protein,HMGB1)。同时分析临床疗效、症状改善时间(止咳时间、发热消退时间;肺部啰音消失时间)及不良反应。结果:观察组总有效率显著高于对照组(P<0.05)。观察组的止咳、退热、肺部啰音消失等时间均显著短于对照组(P<0.05)。治疗后观察组WOB、Raw、PIP、IL-17、IL-33、HMGB1低于对照组(P<0.05);两组患者不良反应发生率无显著差异(P>0.05)。结论:复方异丙托溴铵联合阿莫西林克拉维酸钾治疗大叶性肺炎,能抑制炎症反应,改善呼吸力学,促进临床症状改善,提高临床疗效,且安全性较高。Objective:To analyze the efficacy of compound ipratropium bromide combined with amoxicillin clavulanate potassium in treating children with lobar pneumonia.Methods:Retrospectively collected clinical data of 108 children with lobar pneumonia admitted to our hospital from June 2021 to July 2023.The patients were divided into a control group and an observation group according to their different treatment plans,with 54 cases in each group.The control group was treated with amoxicillin and clavulanate potassium,300 mg·(kg·time)-1,intravenous infusion,once a day.The observation group was treated with amoxicillin,clavulanate potassium,and compound ipratropium bromide aerosol,2 sprays·time-1,twice a day.After 14 days of treatment,respiratory work(WOB),airway resistance(Raw),and peak airway pressure(PIP)were measured using a respiratory function detector.Interleukin 17(IL-17),interleukin 33(IL-33),and high mobility group box-1 protein(HMGB1)were measured using enzyme-linked immunosorbent assay.The clinical efficacy,symptom improvement time(cough relief time,fever subsidence time,lung rale disappearance time),and adverse reactions were analyzed.Results:The total effective rate of the observation group was significantly higher than that of the control group(P<0.05).The time for cough suppression,fever reduction,and disappearance of lung rales in the observation group was significantly shorter than in the control group(P<0.05).After treatment,the WOB,Raw,PIP,IL-17,IL-33,and HMGB1 levels in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compound ipratropium bromide combined with amoxicillin and clavulanate potassium in the treatment of lobar pneumonia can inhibit inflammation,improve respiratory mechanics,promote clinical symptoms,and improve clinical efficacy,with high safety.

关 键 词：大叶性肺炎 复方异丙托溴铵 阿莫西林克拉维酸钾 呼吸力学 血清炎症因子 

分 类 号：R725.6[医药卫生—儿科]